Related Experiment Video
Updated: Jun 18, 2026

Derivation of Thymic Lymphoma T-cell Lines from Atm-/- and p53-/- Mice
Published on: April 3, 2011
Induction of p53 renders ATM-deficient mice refractory to hepatocarcinogenesis
Narci Teoh1, Pawan Pyakurel, Yock Young Dan
1Australian National University Medical School at The Canberra Hospital, Canberra, Australia.
Background & Aims:
p53 Mutations are very common in human hepatocellular carcinoma, and induction of hepatic p53 expression causes lysis of implanted hepatoblastoma cells in a chimeric mouse. Ataxia Telangiectasia Mutated (ATM) kinase senses DNA strand breaks and induces p53. Our aims were to establish whether ATM deficiency alters the carcinogenic response of hepatocytes to diethylnitrosamine (DEN).
Methods:
Male ATM-deficient (ATM(-/-)), heterozygote (ATM(+/-)), and wild-type (WT) mice were injected with DEN at age 15 days, and animals were killed up to 12 months to assess p53, cell cycle, apoptosis, and liver tumor development.
Results:
Whereas >80% of WT and ATM(+/-) mice developed hepatocellular carcinoma (HCC), at 9-12 months, ATM(-/-) mice remained refractory to DEN-induced HCC up to 15 months. At 6 and 9 months, and compared with WT mice, p53 and p19(ARF) expression were greatly enhanced in ATM(-/-) liver associated with up-regulation of ATR and Chk1; cleaved caspase-3 immunohistochemistry and caspase-3 activity were also significantly increased. Whereas livers of DEN-treated ATM(-/-) mice showed markers of senescence (beta-galactosidase, Cxcl-1), up-regulation of telomerase occurred concurrently. The possibility that such balanced senescence could result in immortalization was demonstrated in hepatocytes prepared at 9 months from DEN-treated ATM(-/-) liver.
Conclusions:
Hepatocarcinogenesis is abrogated in ATM-deficient mice in association with induction of ATR, Chk1, p53, and p19(ARF). Resultant cell cycle arrest and apoptosis of DNA-damaged cells are possible mechanisms that underlie this unique "refractoriness" to malignant transformation in DEN-initiated ATM(-/-) hepatocytes. The findings also show that prolonged up-regulation of p53 associated with some features of senescence does not inevitably cause organ failure.
Insights
Mice lacking ATM kinase are protected from liver cancer induced by diethylnitrosamine (DEN). This refractoriness is linked to increased p53 and apoptosis, preventing malignant transformation in hepatocytes.
Area of Science:
- Hepatology
- Cancer Biology
- DNA Damage Response
Background:
- p53 mutations are frequent in human hepatocellular carcinoma (HCC).
- Ataxia Telangiectasia Mutated (ATM) kinase detects DNA breaks and activates p53.
- The role of ATM in DEN-induced hepatocarcinogenesis is unknown.
Purpose of the Study:
- To investigate if ATM deficiency impacts DEN-induced liver cancer.
- To assess the effect of ATM deficiency on p53 activation and hepatocyte response to DEN.
Main Methods:
- Mice with varying ATM gene status (ATM(-/-), ATM(+/-), WT) were injected with DEN.
- Liver tissues were analyzed for p53, cell cycle markers, apoptosis, and tumor development up to 12 months.
Main Results:
- ATM-deficient mice showed no HCC development after DEN exposure, unlike WT and heterozygote mice.
- ATM(-/-) livers exhibited elevated p53, p19ARF, ATR, Chk1, and apoptosis markers.
- Senescence markers were present, alongside telomerase upregulation, suggesting potential immortalization of DEN-treated ATM(-/-) hepatocytes.
Conclusions:
- ATM deficiency abrogates DEN-induced hepatocarcinogenesis.
- ATR/Chk1/p53 pathway activation and subsequent apoptosis/cell cycle arrest protect ATM(-/-) hepatocytes from malignant transformation.
- Sustained p53 induction with senescence features does not necessarily lead to organ failure.
Related Concept Videos
Abnormal Proliferation
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle
The Intrinsic Apoptotic Pathway

